Fennec Pharma

Commercial-stage biopharma Fennec Pharma focuses on PEDMARK, a sodium thiosulfate therapy that passed Phase III to prevent platinum‑induced ototoxicity in pediatric cancer patients, targeting a niche market through oncology specialists in the U.S.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 32
HQ: Research Triangle Park

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
FENC	Fennec Pharma Cap: 0.3B	EQUITY	NMS	USD	CA31447P1009	Active	📈